Selective Multi-Kinase Inhibition Sensitizes Mesenchymal Pancreatic Cancer to Immune Checkpoint Blockade by Remodeling the Tumor Microenvironment

Scientists performed a systematic high-throughput combination drug screen and identified a synergistic interaction between the MEK inhibitor trametinib and the multi-kinase inhibitor nintedanib, which targeted KRAS-directed oncogenic signaling in mesenchymal PDAC.